Drug Combination Details
| General Information of the Combination (ID: C29833) | |||||
|---|---|---|---|---|---|
| Name | Eugenol NP Info | + | Gemcitabine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Cervical cancer
[ICD-11: 2C77]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | IL1B | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HeLa | CVCL_0030 | Endocervical adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Eugenol enhances the chemotherapeutic potential of gemcitabine and induces anticarcinogenic and anti-inflammatory activity in human cervical cancer cells. | |||||
